InspireMD (NSPR) versus Its Rivals Financial Review

InspireMD (NYSE:NSPR) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare InspireMD to similar companies based on the strength of its earnings, profitability, dividends, analyst recommendations, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for InspireMD and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	3	0	3.00
InspireMD Competitors	4248	10477	18202	823	2.46

InspireMD currently has a consensus target price of $4.50, indicating a potential upside of 900.00%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.56%. Given InspireMD’s stronger consensus rating and higher possible upside, equities analysts clearly believe InspireMD is more favorable than its peers.

Risk & Volatility

InspireMD has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, InspireMD’s peers have a beta of 2.53, indicating that their average stock price is 153% more volatile than the S&P 500.

Profitability

This table compares InspireMD and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
InspireMD Competitors	-278.23%	-150.07%	-21.87%

Insider & Institutional Ownership

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 25.0% of InspireMD shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares InspireMD and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InspireMD	$10.84 million	-$19.92 million	-0.70
InspireMD Competitors	$1.90 billion	$137.71 million	10.74

InspireMD’s peers have higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

InspireMD peers beat InspireMD on 7 of the 13 factors compared.

InspireMD Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.